MANHASSET, N.Y.–(BUSINESS WIRE)–Patients with metastatic uveal melanoma (UM), an aggressive eye cancer, often face a survival rate of less than two years once the disease spreads. While established treatment options are limited, to help patients livi…
Category: Business
Samsung Epis Holdings Reports Second Quarter and Half-Year 2026 Financial Results
INCHEON, Korea–(BUSINESS WIRE)– #biosimilars–Samsung Epis Holdings announced its financial results for the second quarter and first half of fiscal year 2026.
Restore Vision and Forge Biologics Announce AAV Development and cGMP Manufacturing Partnership
TOKYO & COLUMBUS, Ohio–(BUSINESS WIRE)–Restore Vision, Inc. (“Restore Vision”), a clinical-stage biotechnology company advancing gene therapies for retinal disorders, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and member …
Radiology Partners Strengthens RP Clinical Services Leadership with Matt Peterson as President and Krishna Nallamshetty, MD, as Chief Operating Officer
NASHVILLE, Tenn.–(BUSINESS WIRE)–Radiology Partners, Inc. (RP), through RP Clinical Services and its affiliated practices, today announced two leadership appointments, effective July 20. Matt Peterson has been named President of RP Clinical Services,…
STAAR Surgical Announces Preliminary Net Sales for Second Quarter 2026
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced strong preliminary net sales for the se…
Riassunto: Compvide™ annuncia una collaborazione strategica con OpZira™ per velocizzare la crescita e lo sviluppo della piattaforma CIMED™
SEATTLE–(BUSINESS WIRE)–Compvide, Inc., il pioniere biotech dell’intelligence dei complementi funzionali tramite la diagnostica innovativa e il monitoraggio della risposta immunitaria, oggi ha dato il via a una collaborazione strategica con OpZira, I…
Compvide™ annonce un partenariat stratégique avec OpZira™ pour accélérer sa croissance et renforcer la plateforme CIMED™
SEATTLE–(BUSINESS WIRE)–Compvide, Inc., société de biotechnologie pionnière dans le domaine de l’intelligence fonctionnelle du système du complément grâce à des outils diagnostiques innovants et au suivi de la réponse immunitaire, a annoncé aujourd’h…
Compvide™ gibt strategische Zusammenarbeit mit OpZira™ bekannt zwecks Wachstum und Förderung der CIMED™ -Plattform
SEATTLE–(BUSINESS WIRE)–Compvide Inc., ein Biotechnologieunternehmen, das durch innovative Diagnostik und die Überwachung von Immunreaktionen Pionierarbeit im Bereich der funktionellen Komplement-Intelligenz leistet, gab heute eine strategische Zusam…
Samenvatting: Compvide™ kondigt strategische samenwerking met OpZira™ aan om de groei te versnellen en het CIMED™-platform verder te ontwikkelen
SEATTLE–(BUSINESS WIRE)–Compvide, Inc., een biotechnologiebedrijf dat baanbrekend werk verricht op het gebied van functionele complementintelligentie door middel van innovatieve diagnostiek en monitoring van immuunreacties, heeft vandaag een strategi…
Resumen: Compvide™ anuncia una colaboración estratégica con OpZira™ para acelerar el crecimiento y desarrollar la plataforma CIMED™
SEATTLE–(BUSINESS WIRE)–Compvide, Inc., una empresa de biotecnología pionera en el campo de la inteligencia del complemento funcional mediante diagnósticos innovadores y la monitorización de la respuesta inmunitaria, ha anunciado hoy una colaboración…
EZContacts Takes On Overpriced Luxury Eyewear With Vesari, Its First In-House Brand
RIDGEFIELD PARK, N.J.–(BUSINESS WIRE)–EZContacts takes on luxury eyewear markups with Vesari. Runway-inspired frames at one honest price: $95, prescription lenses included.
Dompé somministra la dose al primo paziente nello studio di fase 3 su cenegermin-bkbj per la NAION
MILANO & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, azienda biofarmaceutica con attività in Italia e negli Stati Uniti, ha annunciato l’arruolamento del primo paziente in uno studio di fase 3 su cenegermin-bkbj per il trattamento della neuropatia ottic…
Dompé verabreicht erste Dosis in Phase-3-Studie zu Cenegermin-bkbj bei NAION
MAILAND & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, ein biopharmazeutisches Unternehmen mit Niederlassungen in Italien und den USA, gab heute bekannt, dass der erste Patient in eine Phase-3-Studie zu Cenegermin-bkbj für die Behandlung der nicht-arteri…
Dompé administra la dosis al primer paciente en el estudio de fase 3 de cenegermin-bkbj para NOIANA
MILÁN & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, una compañía biofarmacéutica con operaciones en Italia y los Estados Unidos, anunció la inscripción del primer paciente en un estudio de fase 3 de cenegermin-bkbj para el tratamiento de la neuropatía ó…
Dompé dient de eerste patiënt een dosis toe in het fase 3-onderzoek naar Cenegermin-bkbj voor NAION
MILAAN & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, een toonaangevend biofarmaceutisch bedrijf met activiteiten in Italië en de VS, maakt bekend dat de eerste patiënt is ingeschreven voor een fase 3-onderzoek naar cenegermin-bkbj voor de behandeling va…
Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION
MILAN & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé advances cenegermin-bkbj into Phase 3 for NAION, a rapid vision-loss condition with no FDA-approved treatment options.
Dompé administre la première dose à un patient dans le cadre de l’étude de phase 3 sur le cenegermin-bkbj dans le traitement de la NAION
MILAN & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, une société biopharmaceutique présente en Italie et aux États-Unis, a annoncé que le premier patient avait été recruté dans une étude de phase 3 sur le cenegermin-bkbj pour le traitement de la neuropat…
Tenpoint Therapeutics Announces United Kingdom Submission of Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults
LONDON & WARREN, N.J.–(BUSINESS WIRE)–Tenpoint Therapeutics announced the submission of an MAA to the United Kingdom’s MHRA for the review of YUVEZZI™ for the treatment of presbyopia.
Physicians Across Retina Consultants of America Network to Present Key Trial Data and Clinical Insights at ASRS 2026
SOUTHLAKE, Texas–(BUSINESS WIRE)–Retina specialists across the Retina Consultants of America (RCA) network will present clinical trial data, real-world evidence, surgical techniques, and novel treatment approaches across more than 30 sessions at the …
Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting
AUSTIN, Texas–(BUSINESS WIRE)–Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced upcoming oral presentations featuring results from its randomized, head-to-he…